3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
6
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
86
Breast Neoplasms
60
Prostatic Neoplasms
45
Lung Neoplasms
34
Multiple Myeloma
31
Neoplasms
26
Parkinson Disease 4, Autosomal Dominant Lewy Body
22
Colorectal Neoplasms
21
Leukemia, Lymphocytic, Chronic, B-Cell
20
Neoplasm Metastasis
19
Carcinoma, Renal Cell
19
Ovarian Neoplasms
16
Squamous Cell Carcinoma of Head and Neck
13
Leukemia, Myeloid, Acute
13
Endometrial Neoplasms
13
Urinary Bladder Neoplasms
12
Small Cell Lung Carcinoma
12
Recurrence
12
Pancreatic Neoplasms
12
Non-Muscle Invasive Bladder Neoplasms
11
Nasopharyngeal Carcinoma
11
Myasthenia Gravis
11
Triple Negative Breast Neoplasms
10
Lymphoma, Follicular
10
Stomach Neoplasms
9
Lymphoma, Non-Hodgkin
9
Lymphoma, Large B-Cell, Diffuse
9
Fallopian Tube Neoplasms
9
Melanoma
8
Burkitt Lymphoma
8
Interventions
pembrolizumab
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Urologic Neoplasms
×
30 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled